Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
MoonLake Immunotherapeutics (MLTX)
NASDAQ:MLTX
RESEARCH TOOLSreports
MoonLake Immunotherapeutics (MLTX) Stock Price & Analysis
287 Followers
MLTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$35.11 - $64.98
Previous Close$44.77
Volume84.49K
Average Volume (3M)348.20K
Market Cap
$2.86B
Enterprise Value$2.33B
Total Cash (Recent Filing)$547.05M
Total Debt (Recent Filing)$3.66M
Price to Earnings (P/E)―
Beta0.52
Next Earnings
Aug 08, 2024EPS Estimate
-$0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.75
Shares Outstanding63,869,904
10 Day Avg. Volume309,408
30 Day Avg. Volume348,196
Standard Deviation0.22
R-Squared0.08
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)4.95
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-49.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-91.32
Forecast
1Y Price Target
$78.50Price Target Upside75.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
MoonLake Immunotherapeutics News
PremiumCompany Announcements
MoonLake Immunotherapeutics Advances in Psoriatic Arthritis Trial
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentMLTX announced regulatory alignment with both FDA and EMA on the clinical development plan for lead asset sonelokimab in psoriatic arthritis.
Market OpportunitySLK is well-positioned to become a dominant, if not the leading option for physicians to treat moderate-to-severe HS.
Regulatory ProgressMoonLake announced that the company has effectively clarified the U.S. and E.U. regulatory paths for its Phase 3 (IZAR) study and development path for sonelokimab (SLK) in psoriatic arthritis (PsA).
Bears Say
Commercial SuccessThe path to succeed commercially will be challenging due to heavy payer contracting that favor Humira and its biosimilars in 1L.
Market DifferentiationAnalyst did not see any convincing evidence of SLK’s differentiation in a very crowded and efficacious PsA market.
Stock UpsideThe lack of catalysts for rest of the year and MLTX not prioritizing a partnership prior to Ph. 3 data means little upside for the stock in 2024.
---
Ownership Overview
63.42% Insiders
14.35% Mutual Funds
0.89% Other Institutional Investors
21.34% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MLTX FAQ
What was MoonLake Immunotherapeutics’s price range in the past 12 months?
MoonLake Immunotherapeutics lowest stock price was $35.11 and its highest was $64.98 in the past 12 months.
What is MoonLake Immunotherapeutics’s market cap?
Currently, no data Available
When is MoonLake Immunotherapeutics’s upcoming earnings report date?
MoonLake Immunotherapeutics’s upcoming earnings report date is Aug 08, 2024 which is in 11 days.
How were MoonLake Immunotherapeutics’s earnings last quarter?
MoonLake Immunotherapeutics released its earnings results on May 07, 2024. The company reported -$0.22 earnings per share for the quarter, missing the consensus estimate of -$0.193 by -$0.027.
Is MoonLake Immunotherapeutics overvalued?
According to Wall Street analysts MoonLake Immunotherapeutics’s price is currently Undervalued.
Does MoonLake Immunotherapeutics pay dividends?
MoonLake Immunotherapeutics does not currently pay dividends.
What is MoonLake Immunotherapeutics’s EPS estimate?
MoonLake Immunotherapeutics’s EPS estimate is -$0.28.
How many shares outstanding does MoonLake Immunotherapeutics have?
MoonLake Immunotherapeutics has 62,874,638 shares outstanding.
What happened to MoonLake Immunotherapeutics’s price movement after its last earnings report?
MoonLake Immunotherapeutics reported an EPS of -$0.22 in its last earnings report, missing expectations of -$0.193. Following the earnings report the stock price went down -1.932%.
Which hedge fund is a major shareholder of MoonLake Immunotherapeutics?
Among the largest hedge funds holding MoonLake Immunotherapeutics’s share is Perceptive Advisors LLC. It holds MoonLake Immunotherapeutics’s shares valued at 17M.
---
MoonLake Immunotherapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$78.50 (75.34% Upside)
$78.50 (75.34% Upside)
Blogger Sentiment
Bullish
MLTX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 325.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 12.2%
Last 30 Days ▼ 12.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-24.13%
12-Months-Change
Fundamentals
Return on Equity
-13.92%
Trailing 12-Months
Asset Growth
744.53%
Trailing 12-Months
Company Description
MoonLake Immunotherapeutics
Helix Acquisition Corp is a blank check company.
---
MLTX Stock 12 Month Forecast
Average Price Target
$78.50
▲(75.34% Upside)
Technical Analysis
Best Analysts Covering MLTX
1 Year
1 Year Success Rate
11/16 ratings generated profit
1 Year Average Return
+122.59%
reiterated a buy rating 2 months ago
Copying Thomas Smith's trades and holding each position for 1 Year would result in 68.75% of your transactions generating a profit, with an average return of +122.59% per trade.
---